[Why are some drugs so expensive? The price policy of pharmaceutical companies--"digging the grave of our health insurance-system"?].
A decisive influence on the attractiveness of the German drug market is exerted by the institutions responsible for the prescribability of a drug in the framework of the Statutory Health Insurance (SHI). In this most lucrative segment of the German market, a host of reforms in recent years has led to declining transparency, where the short-lived regulatory interventions aimed - with limited success - at containing the increase in expenditure on drugs. From 1997 to 2003, however, new and patented drugs were largely protected against regulatory measures, such as fixed reimbursement rates (reference prices). However, only little use was made of this additional promotion of research activities. The majority of the new drugs in this period were me-too products, which only rarely had therapeutic advantages or advantages in the price competition with established medicines. In addition, the pharmaceutical companies widely use the privilege to set a price for drugs being prescribed in the SHI without undertaking any negotiations or presenting cost-effectiveness studies, which is unique in the European comparison. In future, the decision regarding the reimbursability of, or the reimbursable amount for, a preparation should thus be geared to lasting, transparent and unequivocal criteria guided by efficiency optimization and therapeutic progress.
Glaeske
Gerd
G
Zentrum für Sozialpolitik (ZeS), Universität Bremen. gglaeske@zes.uni-bremen.de
D000329:Advertising / Q000191:economics; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D004345:Drug Industry / Q000191:economics* / Q000592:standards; D004358:Drug Therapy / Q000191:economics*; D005858:Germany; D007348:Insurance, Health / Q000592:standards / Q000639:trends*; D011785:Quality Assurance, Health Care